• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非小细胞肺癌患者能量间隙与抗程序性细胞死亡蛋白 1 免疫检查点抑制剂敏感性的关系:ELY-2 研究。

Relationship between energetic gap and sensitivity to anti-programmed cell death 1 immune checkpoint inhibitors in non-small cell lung cancer patients: The ELY-2 study.

机构信息

Department of Medical Oncology, Cochin Hospital, AP-HP, CARPEM, France; Immunomodulatory Therapies Multidisciplinary Study Group (CERTIM), Paris, France.

Department of Medical Oncology, Cochin Hospital, AP-HP, CARPEM, France; Immunomodulatory Therapies Multidisciplinary Study Group (CERTIM), Paris, France.

出版信息

Clin Nutr ESPEN. 2024 Dec;64:44-50. doi: 10.1016/j.clnesp.2024.09.002. Epub 2024 Sep 6.

DOI:10.1016/j.clnesp.2024.09.002
PMID:39244156
Abstract

BACKGROUND & AIMS: We previously reported in the ELY prospective study that increased resting energy expenditure (REE) - so-called hypermetabolism - worsened tumor response, 6-month progression-free (PFS) and overall survival (OS) in metastatic non-small cell lung cancer (mNSCLC) patients treated with immune checkpoint inhibitors (ICI). Here, we investigated the effect of caloric coverage on the sensitivity to ICI.

METHODS

We retrospectively analysed a multicentric database of mNSCLC patients treated with ICI. All patients had a baseline nutritional assessment including REE measured with indirect calorimetry and a dietitian estimation of food intakes. Measured/theoretical REE ≥110% defined hypermetabolism. Intakes ≥90% of estimated needs defined caloric coverage. The primary endpoint was PFS. Secondary endpoints included response rate and OS.

RESULTS

Among 162 patients, 84 (51.9%) were normometabolic, and 78 (48.1%) hypermetabolic. In hypermetabolic patients, 40 (51.3%) met their caloric needs (group A) while 38 (48.7%) did not (group B). Median PFS was 4.3 vs. 1.9 months in groups A and B, respectively (HR: 0.49, 95%CI [0.31-0.80], p = 0.004). The PFS achieved in the group A and in normometabolic patients were similar (HR: 0.99, 95%CI [0.65-1.51], p = 0.95). In multivariate analysis, caloric coverage was independently associated with improved PFS in hypermetabolic patients (HR: 0.56, 95%CI [0.31-0.99], p = 0.048). Among hypermetabolic patients, the median OS was higher in the group A (HR: 0.58, 95%CI [0.35-0.95], p = 0.03).

CONCLUSION

Energy supply is a critical determinant of the sensitivity to ICI in NSCLC patients. A randomized study to evaluate the benefit of early nutritional intervention is warranted.

摘要

背景与目的

我们之前在 ELY 前瞻性研究中报告称,在接受免疫检查点抑制剂(ICI)治疗的转移性非小细胞肺癌(mNSCLC)患者中,静息能量消耗(REE)增加(所谓的高代谢)会导致肿瘤反应、6 个月无进展(PFS)和总生存(OS)恶化。在此,我们研究了热量覆盖对 ICI 敏感性的影响。

方法

我们回顾性分析了接受 ICI 治疗的 mNSCLC 患者的多中心数据库。所有患者均接受基线营养评估,包括间接测热法测量 REE 和营养师估计的食物摄入量。测量/理论 REE≥110%定义为高代谢。摄入量≥估计需求的 90%定义为热量覆盖。主要终点是 PFS。次要终点包括反应率和 OS。

结果

在 162 名患者中,84 名(51.9%)为正常代谢,78 名(48.1%)为高代谢。在高代谢患者中,40 名(51.3%)满足其热量需求(A 组),而 38 名(48.7%)未满足(B 组)。A 组和 B 组的中位 PFS 分别为 4.3 个月和 1.9 个月(HR:0.49,95%CI [0.31-0.80],p=0.004)。A 组和正常代谢患者的 PFS 相似(HR:0.99,95%CI [0.65-1.51],p=0.95)。多变量分析显示,热量覆盖与高代谢患者的 PFS 改善独立相关(HR:0.56,95%CI [0.31-0.99],p=0.048)。在高代谢患者中,A 组的中位 OS 更高(HR:0.58,95%CI [0.35-0.95],p=0.03)。

结论

能量供应是 NSCLC 患者对 ICI 敏感性的关键决定因素。需要进行一项随机研究来评估早期营养干预的益处。

相似文献

1
Relationship between energetic gap and sensitivity to anti-programmed cell death 1 immune checkpoint inhibitors in non-small cell lung cancer patients: The ELY-2 study.非小细胞肺癌患者能量间隙与抗程序性细胞死亡蛋白 1 免疫检查点抑制剂敏感性的关系:ELY-2 研究。
Clin Nutr ESPEN. 2024 Dec;64:44-50. doi: 10.1016/j.clnesp.2024.09.002. Epub 2024 Sep 6.
2
Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study.在 CERTIM 队列中,研究了宿主依赖性、PD-L1 非依赖性生物标志物在接受抗 PD-1 免疫检查点抑制剂(ICI)治疗的转移性非小细胞肺癌(mNSCLC)患者中预测 6 个月无进展生存期的开发和验证:ELY 研究。
EBioMedicine. 2021 Nov;73:103630. doi: 10.1016/j.ebiom.2021.103630. Epub 2021 Oct 20.
3
Impact of Antibiotics and Proton Pump Inhibitors on Efficacy and Tolerance of Anti-PD-1 Immune Checkpoint Inhibitors.抗生素和质子泵抑制剂对 PD-1 免疫检查点抑制剂疗效和耐受性的影响。
Front Immunol. 2021 Oct 27;12:716317. doi: 10.3389/fimmu.2021.716317. eCollection 2021.
4
The Relationship of Diabetes Mellitus to Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer.糖尿病与晚期非小细胞肺癌患者免疫检查点抑制剂疗效的关系。
Oncology. 2021;99(9):555-561. doi: 10.1159/000516671. Epub 2021 Jul 9.
5
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.比较单药或联合免疫检查点抑制剂与含或不含贝伐珠单抗的一线含铂化疗方案用于晚期非小细胞肺癌患者。
Cochrane Database Syst Rev. 2020 Dec 14;12(12):CD013257. doi: 10.1002/14651858.CD013257.pub2.
6
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.比较单药或联合免疫检查点抑制剂与一线含或不含贝伐珠单抗的铂类化疗方案用于晚期非小细胞肺癌患者。
Cochrane Database Syst Rev. 2021 Apr 30;4(4):CD013257. doi: 10.1002/14651858.CD013257.pub3.
7
Association of Energy Expenditure and Efficacy in Metastatic Renal Cell Carcinoma Patients Treated with Nivolumab.接受纳武单抗治疗的转移性肾细胞癌患者的能量消耗与疗效的关联
Cancers (Basel). 2022 Jun 30;14(13):3214. doi: 10.3390/cancers14133214.
8
[Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].[程序性死亡蛋白1/程序性死亡配体1抑制剂治疗转移性非小细胞肺癌患者的疗效及预后预测生物标志物的真实世界研究]
Zhonghua Zhong Liu Za Zhi. 2022 May 23;44(5):416-424. doi: 10.3760/cma.j.cn112152-20210709-00504.
9
Lower tumor volume is associated with increased benefit from immune checkpoint inhibitors in patients with advanced non-small-cell lung cancer.肿瘤体积越小,晚期非小细胞肺癌患者从免疫检查点抑制剂治疗中获益越大。
Asia Pac J Clin Oncol. 2021 Apr;17(2):e125-e131. doi: 10.1111/ajco.13360. Epub 2020 Aug 6.
10
Impact of natremia on metastatic non small cell lung cancer patients receiving immune checkpoint inhibitors.钠血症对接受免疫检查点抑制剂治疗的转移性非小细胞肺癌患者的影响。
Sci Rep. 2024 Nov 29;14(1):29655. doi: 10.1038/s41598-024-81458-z.